The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir

被引:178
|
作者
Kempf, DJ
Rode, RA
Xu, Y
Sun, E
Heath-Chiozzi, ME
Valdes, J
Japour, AJ
Danner, S
Boucher, C
Molla, A
Leonard, JM
机构
[1] Abbott Labs, Antiviral Venture, Div Pharmaceut Prod, Abbott Pk, IL 60064 USA
[2] Abbott Labs, Dept Biostat, Abbott Pk, IL 60064 USA
[3] Abbott Labs, Dept Infect Dis Res, Abbott Pk, IL 60064 USA
[4] Univ Amsterdam, Acad Med Ctr, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands
[5] Univ Utrecht, Univ Hosp, Eijkman Winkler Inst Med & Clin MIcrobiol, Utrecht, Netherlands
关键词
viral load; durability of response; protease inhibitor; resistance;
D O I
10.1097/00002030-199805000-00001
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To determine markers that are associated with the durability of virologic response to therapy with HIV protease inhibitors in HIV-infected individuals. Design: This study encompassed two retrospective analyses of the duration of virologic response to protease inhibitor therapy. The first analysis included 29 patients receiving either monotherapy or combination therapy with the protease inhibitor ritonavir whose plasma HIV RNA levels rebounded from the point of greatest decline with mutations associated with resistance to ritonavir. The second analysis included a cohort of 102 patients who initially responded to randomized treatment with either monotherapy with ritonavir or combination therapy with ritonavir and zidovudine. Methods: Durability of response was defined as the time from the initiation of therapy to the point at which plasma HIV RNA displayed a sustained increase of at least 0.6 log(10) copies/ml from the nadir value. In the first analysis, durability of response was analyzed with respect to baseline HIV RNA, HIV RNA at the nadir, and the drop in HIV RNA from baseline to the nadir. In the second analysis, time to rebound was examined using Kaplan-Meier analysis, stratifying by either baseline HIV RNA or HIV RNA at the nadir. Results: In both analyses, the durability of response was not highly associated with either baseline RNA or the magnitude of RNA decline from baseline. Instead, a strong relationship was observed between the durability of response and the nadir plasma HIV-1 RNA value (P < 0.01). The nadir in viral load was generally reached after 12 weeks of randomized therapy. Conclusions: Viral RNA determinations at intermediate timepoints may be prognostic of impending virologic failure of protease inhibitor therapy. Therapeutic strategies that allow intensification of initial antiretroviral regimens in the subset of patients with incomplete virological response before the emergence of high level resistance should be investigated. (C) 1998 Rapid Science Ltd.
引用
收藏
页码:F9 / F14
页数:6
相关论文
共 50 条
  • [31] Design of a folding inhibitor of the HIV-1 protease
    Tiana, G
    Broglia, RA
    Sutto, L
    Provasi, D
    MOLECULAR SIMULATION, 2005, 31 (11) : 765 - 771
  • [32] Atazanavir: a novel HIV-1 protease inhibitor
    Piliero, PJ
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (09) : 1295 - 1301
  • [33] Interdependence of Inhibitor Recognition in HIV-1 Protease
    Paulsen, Janet L.
    Leidner, Florian
    Ragland, Debra A.
    Yilmaz, Nese Kurt
    Schiffer, Celia A.
    JOURNAL OF CHEMICAL THEORY AND COMPUTATION, 2017, 13 (05) : 2300 - 2309
  • [34] THE STRUCTURES OF INHIBITOR COMPLEXES OF HIV-1 PROTEASE
    WLODAWER, A
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1990, 200 : 82 - MEDI
  • [35] CAN THE EVOLUTION OF INFECTION BY HIV-1 BE PREDICTED
    MUGA, R
    TOR, J
    MEDICINA CLINICA, 1992, 99 (17): : 653 - 655
  • [36] RNA interference and HIV-1 infection
    Kanzaki, Luis Isamu Barros
    Ornelas, Socrates Souza
    Arganaraz, Enrique R.
    REVIEWS IN MEDICAL VIROLOGY, 2008, 18 (01) : 5 - 18
  • [37] Coamplification of HIV-1 Proviral DNA and Viral RNA in Assays Used for Quantification of HIV-1 RNA
    Wan, H.
    Seth, A.
    Rainen, L.
    Fernandes, H.
    JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (06) : 2186 - 2190
  • [38] Older age and plasma viral load in HIV-1 infection
    Goodkin, K
    Shapshak, P
    Asthana, D
    Zheng, WL
    Concha, M
    Wilkie, FL
    Molina, R
    Lee, D
    Suarez, P
    Symes, S
    Khamis, I
    AIDS, 2004, 18 : S87 - S98
  • [39] Raltegravir, an HIV-1 integrase inhibitor for HIV infection
    Cabrera, Cecilia
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2008, 9 (08) : 885 - 898
  • [40] HIV-1 in placentas of untreated HIV-1-infected women in relation to viral transmission, infectious HIV-1 and RNA load in plasma
    Dictor, M
    Lindgren, S
    Bont, J
    Anzén, B
    Lidman, K
    Wallin, KL
    Navér, L
    Bohlin, AB
    Ehrnst, A
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2001, 33 (01) : 27 - 32